P60.09 Real-World Readiness of US Laboratories to Test Metastatic NSCLC Patients for Rare Actionable Genomic Variants by NGS
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2021.08.630
Abstract: Introduction: Various rare driver genomic variants have been investigated in metastatic non-squamous non-small cell lung cancer (mNSCLC). Individually they are considered rare ( read more here.
Keywords: medicine; real world; mnsclc; genomic variants ... See more keywords
Abstract CT246: A phase 2 multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC)
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct246
Abstract: Background Patients with mNSCLC without actionable driver mutation(s) who have progressed after cytotoxic chemotherapy plus immune checkpoint inhibitors (ICI) ± bevacizumab have limited treatment options and represent an unmet need. The safety and efficacy of… read more here.
Keywords: therapy; cancer; mnsclc; cell ... See more keywords
Abstract 729: The economic and healthcare resource utilization of metastatic non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-729
Abstract: Background: The objective of this review was to examine the economic and health care resource utilization (HCRU) burden of patients with metastatic non-small cell lung cancer (mNSCLC), globally. Methods: A systematic literature review of PubMed… read more here.
Keywords: therapy; mnsclc; treatment; cancer ... See more keywords